FONT-SIZE Plus   Neg

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL) and Pfizer Inc. (PFE) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Company on Thursday reported a 56 percent fall in profit for the third quarter from last year, reflecting safety-recall expenses, product launch costs and lower profit in North America. However, adjusted earnings per share beat analysts' estimates. Social media site Twitter Inc. (TWTR) reported a narrower loss for the third-quarter quarter, while quarterly revenue increased 8% from the prior year. Adjusted earnings per share topped analysts' expectations. It will reduce about 9% of its global workforce. It updated its outlook for the full year 2016 and provided guidance for the fourth quarter of 2016. Dow Chemical Co. (DOW) reported a profit for the third-quarter declined about 44 percent from the prior year, reflecting a $0.13 per share charge related to the Dow Corning ownership restructure and a $0.11 per share charge for transactions and productivity actions. Results in the year-ago period reflect a $0.32 per share gain from the Agrofresh divestiture.
comments powered by Disqus
Follow RTT